/ Cadila's Mesalamine Delayed-Release Tablets Launched In US ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 19 July 2017

Zydus Cadila, an India-based pharmaceutical company, announced on Wednesday that the company has launched its Mesalamine Delayed Release tablets USP, 1.2g in the United States.

The drug specialise for the treatment of mild to moderate ulcerative colitis which affects approximately 700,000 people in the US.

The company was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda and currently is the only generic option available in the American market.

The stock was trading at Rs 528.75, up by 0.72 % on BSE at 0955 hours. It opened on Wednesday at Rs 529, while on Tuesday it closed at Rs 524.95. It touched its intraday high and low at Rs 534.10 and Rs 527.35, respectively.

The group has received a total 26 final ANDA approvals from USFDA and two tentative ANDA approvals since January 2017.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717